C.E.R.A. Anti-Anemia Drug Maintained Stable Hemoglobin Levels In Dialysis Patients With Up To Once Every Four Week Dosing, Phase III Clinical Studies

... Dialysis patients treated withshort-acting and frequently administered epoetin were switched to a onceevery two week or once every four week treatment and maintained stablehemoglobin (Hb) levels, according to data presented today. (1,2) This newtreatment is Roche's investigational Continuous Erythropoietin ReceptorActivator (C.E.R.A. [click link for full article] ...